Humira, Keytruda, Opdivo, Avastin, Rituxan, Stelara, Herceptin, Enbrel

DUBLIN, August 3, 2021 / PRNewswire / – The Top-selling biologics market, 2021-2030: focus on product landscape assessment, ongoing clinical trials, analysis of promotional content, alternative lifecycle management strategies, biosimilar competition, cost comparison annual salaries, sales trends and future opportunities ” report was added to ResearchAndMarkets.com offer.

The report “Top Selling Biologics Market, 2021-2030” presents an in-depth study of the current market landscape and the future potential of top-selling biologics available for the treatment of a variety of disease indications. The study includes an in-depth analysis, highlighting key initiatives undertaken by various actors engaged in this field.

One of the main objectives of the report was to estimate the size of the existing market and the potential for future growth in the top-selling organic products market over the next decade. Based on several parameters, such as historical sales, future competition from other biologics and biosimilars, as well as the impending expiration of patents, we have provided informed estimates on the financial development of the market for the period 2020. -2030.

It further includes forecasts based on sales of over 60 top-selling organic products. The report also provides details on the probable distribution of the current and projected opportunity by type of biologic (monoclonal antibody, hormone, enzyme, fusion protein, interferon, gene therapy, and others) and major players. In order to account for future uncertainties and add robustness to our model, we have provided three market forecast scenarios namely conservative, baseline and bullish scenarios, representing different avenues for industry growth.

Today, biologics represent the fastest growing product segment within the global pharmaceutical industry. Indeed, from September 2020, more than 430 biologic procedures have been approved for the treatment of various disease indications in the United States and Europe. Due to the advantages they offer, biologics are in great demand for the treatment of different disease indications. It is a well-known fact that antibodies have emerged as the major therapeutic breakthroughs and have achieved significant success over the past two decades.

There are other vast opportunities for organics in the foreseeable future. This segment of the healthcare industry is in the midst of many innovations; examples include antibody-drug conjugates, immunotherapies, bispecific antibodies, combination therapies, and cell and gene therapies. These developments have paved the way for major disruption, creating more therapeutic targets and ultimately taking personalized healthcare to amazing new heights.

Despite their complex and expensive manufacturing protocols, biopharmaceuticals (once approved) are highly profitable assets. In the recent past, many biological interventions have achieved blockbuster status (in some cases, recording income worth more than $ 4 billion in a year); prominent examples include (based on declining revenue generated in 2020) Humira, Keytruda, Stelara, Opdivo, Avastin, Trulicity, Enbrel, OcrevusT and Rituxan.

Together, the aforementioned products generated sales worth nearly 80 billion dollars in 2020 alone. Although the patents protecting some of these successful drugs have already expired, sales of the original product have not been significantly affected. For example, there are several approved biosimilar versions of Abbvie’s Humira, but the company has reported annual worldwide revenues of approximately $ 19 billion of sales of this drug alone.

For several other top-selling biologics, patents covering affiliated intellectual property are expected to expire soon, opening the market to competition from follow-on biologics. However, there are ways in which innovators can expand their market exclusivity and delay entry of biosimilars; Popular product lifecycle management strategies include obtaining marketing authorization (and exclusivity) in a new geographic area, proof of therapeutic benefit for a different disease indication ( than that which the product was originally authorized to treat), developing a new formulation of the drug, demonstrating therapeutic benefit in combination with another drug / therapy, and making the product available in a new device / system drug administration.

In other words, companies that have developed successful biologics should continue to benefit from their respective high value assets in the short to medium term. However, we expect the market for these products to grow steadily and then stabilize, before gradually declining over time as impending expirations of patents (including those that have been extended) pave the way for biosimilars.

Answers to key questions

  • Which biologics have achieved blockbuster status in the past 1-2 years?
  • Who are the main players involved in the development of the best-selling organic products?
  • What key clinical conditions are currently targeted by top-selling biologics?
  • What are the historical global sales of the best-selling organic products?
  • What product lifecycle management strategies are most commonly adopted by players to extend the lifespan of their top-selling products?
  • What is the current annual cost of processing associated with top selling biologics?
  • Which regions have become key centers for conducting clinical studies focusing on top-selling biologics?
  • How has the biosimilars landscape in this market evolved over the past few years?
  • What factors are likely to influence the evolution of this market?
  • How are current and future market opportunities likely to be distributed among key market segments?

Main topics covered:

1. Preface

2. Executive summary

3. Presentation

4. Market overview

5. Global Sales Analysis of Top Selling Organic Products

6. Analysis of clinical trials

7. Promotional analysis

8. Product lifecycle management strategies

9. Cost price analysis

10. Biosimilars

11. Market sizing and opportunity analysis

12. Conclusion

13. Annex 1: Tabulated data

14. Annex 2: List of companies and organizations

Companies mentioned

  • AbbVie
  • Alexion Pharmaceutical
  • Allergan
  • Amgen
  • AstraZeneca
  • Bayer
  • Biogen
  • Biomarine
  • Bristol-Myers Squibb
  • Chugai Pharmaceutical
  • Daiichi sankyo
  • Eli lilly
  • Genentech
  • GlaxoSmithKline
  • ImClone
  • Immunex
  • Janssen Biotech
  • Johnson & johnson
  • MedImmune
  • Merck
  • Novartis
  • Novo Nordisk
  • Regeneron Pharmaceuticals
  • rock
  • Sanofi
  • Torii Pharmaceutical
  • UCB
  • Vifor Pharma

For more information on this report, visit https://www.researchandmarkets.com/r/u49xcj

Media contact:

Research and markets
Laura Wood, senior
[email protected]

For EST office hours, call + 1-917-300-0470
For USA / CAN call toll free + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900

US Fax: 646-607-1907
Fax (outside the United States): + 353-1-481-1716

SOURCE Research and Markets

Related links

http://www.researchandmarkets.com

Source link

About Michael Bill

Check Also

SELLAS Life Sciences announces derivative settlement

NEW YORK, September 23, 2021 (GLOBE NEWSWIRE) – SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) …

Leave a Reply

Your email address will not be published. Required fields are marked *